Neuro startup stock craters after PhIII study marred with ‘significant deviation’ from trial protocol

A Neva­da start­up re­search­ing an Alzheimer’s drug saw its stock crater Wednes­day morn­ing af­ter it re­port­ed Phase III re­sults that in­clud­ed da­ta in­tegri­ty is­sues at sev­er­al clin­i­cal tri­al sites.

Shares of BioVie $BIVI fell near­ly 70% in ear­ly Wednes­day trad­ing fol­low­ing the com­pa­ny’s re­veal of Phase III ef­fi­ca­cy da­ta. BioVie’s drug, known as NE3107, missed its pri­ma­ry end­point due to what the com­pa­ny de­scribed as “sig­nif­i­cant de­vi­a­tion from pro­to­col and Good Clin­i­cal Prac­tice (GCP) vi­o­la­tions” from 15 of its 39 tri­al sites, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.